

Andy Beshear GOVERNOR

CABINET FOR HEALTH AND FAMILY SERVICES

DEPARTMENT FOR MEDICAID SERVICES

275 East Main Street, 6W-A Frankfort, Kentucky 40621

@chfsky | CHFS.KY.GOV

Steven Stack, MD SECRETARY

> Lisa D. Lee COMMISSIONER

Casgevy Clinical Authorization Criteria

- Confirmatory genetic testing; AND
- Failure or intolerance to hydroxyurea (defined as being unable to take hydroxyurea per health care professional judgment) at any point in the past.; AND
- Age twelve (12) years and older at the expected time of gene therapy administration; AND
- Clinically stable and fit for transplantation; AND
- Prescribed by or in consultation with a board-certified hematologist with Sickle Cell Disease expertise; AND
- Experienced recurrent VOCs (defined as more than or equal to two (2) documented VOCs per year in the previous twenty-four (24) months, based on provider attestation); AND
- Casgevy will not be administered during pregnancy due to the risk of myeloablative conditioning.; AND
- Patients will not have a history of prior allogeneic or autologous Hematopoietic Stem Cell transplant.; AND
- Casgevy will not be used in patients with active HIV-1, HIV-2, HBV, or HCV.; AND
- Casgevy will not be administered during pregnancy and/or breastfeeding will be discontinued due to the potential risks associated with myeloablative conditioning.; AND
- Authorization will be approved for 1 year if the patient meets all of the criteria above.





